laurolitsine hydrochloride (MedChemExpress)

MedChemExpress laurolitsine hydrochloride

Molecular docking visualization. ( A ) Molecular docking mode diagram of <t>Laurolitsine</t> with ADRB2; ( B ) Molecular docking mode diagram of Hecogenin with MAPK8; ( C ) Molecular docking mode diagram of Hecogenin with MAPK9; ( D ) Molecular docking mode diagram of Hecogenin with MAPK10.

Laurolitsine Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-n2352a/Laurolitsine+hydrochloride/pmc12563024-85-3-15
Average 93 stars, based on 1 article reviews

laurolitsine hydrochloride - by Bioz Stars, 2026-10

93/100 stars

Buy from Supplier

Image Search Results

Molecular docking visualization. ( A ) Molecular docking mode diagram of Laurolitsine with ADRB2; ( B ) Molecular docking mode diagram of Hecogenin with MAPK8; ( C ) Molecular docking mode diagram of Hecogenin with MAPK9; ( D ) Molecular docking mode diagram of Hecogenin with MAPK10.

Journal: Current Issues in Molecular Biology

Article Title: Cinnamomum migao H.W. Li Ethanol-Water Extract Suppresses IL-6 Production in Cardiac Fibroblasts: Mechanisms Elucidated via UPLC-Q-TOF-MS, Network Pharmacology, and Experimental Assays

doi: 10.3390/cimb47100798

Figure Lengend Snippet: Molecular docking visualization. ( A ) Molecular docking mode diagram of Laurolitsine with ADRB2; ( B ) Molecular docking mode diagram of Hecogenin with MAPK8; ( C ) Molecular docking mode diagram of Hecogenin with MAPK9; ( D ) Molecular docking mode diagram of Hecogenin with MAPK10.

Article Snippet: Isoprenaline hydrochloride (HY-B0468), Laurolitsine hydrochloride (HY-N2352A), Hecogenin (HY-N1422), and Propranolol hydrochloride (HY-B0573) were purchased from MedChemExpress Co., Ltd. (Monmouth Junction, NJ, USA).

Techniques:

Screening of the optimal intervention concentrations of MG-EWE, Laurolitsine, and Hecogenin. ( A ) Effects of different concentrations of Laurolitsine on CFs viability; ( B ) Effect of different concentrations of Hecogenin on CFs viability; ( C ) Effect of different concentrations of MG-EWE on CFs viability; ( D ) Effects of different concentrations of MG-EWE, Laurolitsine, and Hecogenin on ISO-induced CFs viability; ( E ) IL-6 content in the cell supernatant of each group. Compared to the control group, #### p < 0.0001. Compared to the ISO model group, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: Current Issues in Molecular Biology

doi: 10.3390/cimb47100798

Figure Lengend Snippet: Screening of the optimal intervention concentrations of MG-EWE, Laurolitsine, and Hecogenin. ( A ) Effects of different concentrations of Laurolitsine on CFs viability; ( B ) Effect of different concentrations of Hecogenin on CFs viability; ( C ) Effect of different concentrations of MG-EWE on CFs viability; ( D ) Effects of different concentrations of MG-EWE, Laurolitsine, and Hecogenin on ISO-induced CFs viability; ( E ) IL-6 content in the cell supernatant of each group. Compared to the control group, #### p < 0.0001. Compared to the ISO model group, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Techniques: Control

The Migration ability of CFs in each group, original magnification: 200×. ( A ) Representative images from the Transwell assay showing the migration of CFs treated with MG-EWE, Laurolitsine, and Hecogenin; ( B ) Quantitative analysis of the effects of MG-EWE, Laurolitsine, and Hecogenin on the number of ISO-induced CFs migration. Compared to the control group, #### p < 0.0001. Compared to the ISO model group, ** p < 0.01, **** p < 0.0001.

Journal: Current Issues in Molecular Biology

doi: 10.3390/cimb47100798

Figure Lengend Snippet: The Migration ability of CFs in each group, original magnification: 200×. ( A ) Representative images from the Transwell assay showing the migration of CFs treated with MG-EWE, Laurolitsine, and Hecogenin; ( B ) Quantitative analysis of the effects of MG-EWE, Laurolitsine, and Hecogenin on the number of ISO-induced CFs migration. Compared to the control group, #### p < 0.0001. Compared to the ISO model group, ** p < 0.01, **** p < 0.0001.

Techniques: Migration, Transwell Assay, Control

The schematic diagram illustrates the molecular mechanism through which MG suppresses IL-6 production in cardiac fibroblasts (CFs): in the isoproterenol (ISO)-induced CFs transdifferentiation model, MG-EWE and its active components Laurolitsine and Hecogenin can inhibit the abnormal activation of the ADRB2/JNK/c-Jun signaling pathway. When ISO binds to the ADRB2 receptor on the cell membrane surface of CFs, it initiates a downstream signaling cascade. Activation of this receptor leads to the phosphorylation of key signaling molecules, including JNK1/2/3 and c-Jun, thereby activating the JNK/c-Jun signaling pathway. The activated JNK1/2/3 translocates from the cytoplasm to the nucleus and further phosphorylates the transcription factor c-Jun within the nucleus, enhancing its transcriptional activity. This ultimately promotes the transcription of the IL-6 gene and increases its protein expression. Laurolitsine functions by inhibiting the activation of ADRB2 on the CFs cell membrane surface, while Hecogenin inhibits the phosphorylation of JNK, thereby blocking the subsequent phosphorylation of c-Jun. Together, these actions result in the joint inhibition of IL-6 production.

Journal: Current Issues in Molecular Biology

doi: 10.3390/cimb47100798

Figure Lengend Snippet: The schematic diagram illustrates the molecular mechanism through which MG suppresses IL-6 production in cardiac fibroblasts (CFs): in the isoproterenol (ISO)-induced CFs transdifferentiation model, MG-EWE and its active components Laurolitsine and Hecogenin can inhibit the abnormal activation of the ADRB2/JNK/c-Jun signaling pathway. When ISO binds to the ADRB2 receptor on the cell membrane surface of CFs, it initiates a downstream signaling cascade. Activation of this receptor leads to the phosphorylation of key signaling molecules, including JNK1/2/3 and c-Jun, thereby activating the JNK/c-Jun signaling pathway. The activated JNK1/2/3 translocates from the cytoplasm to the nucleus and further phosphorylates the transcription factor c-Jun within the nucleus, enhancing its transcriptional activity. This ultimately promotes the transcription of the IL-6 gene and increases its protein expression. Laurolitsine functions by inhibiting the activation of ADRB2 on the CFs cell membrane surface, while Hecogenin inhibits the phosphorylation of JNK, thereby blocking the subsequent phosphorylation of c-Jun. Together, these actions result in the joint inhibition of IL-6 production.

Techniques: Activation Assay, Membrane, Phospho-proteomics, Activity Assay, Expressing, Blocking Assay, Inhibition

hy-n2352a Search Results

Image Search Results